申请人:Pierre Fabre Medicament
公开号:US06191130B1
公开(公告)日:2001-02-20
The invention concerns novel cyclohexane derivatives difunctionalised in 1.4 of general formula (1) in which A represents a group such as (IIa) in which Ar itself represents an aromatic structure such as phenyl or pyrimidinyl optionally substituted by one or several groups such as C1-C3 alkyl, C1-C3 alkoxy, trifluoromethyl or halogen (IIb); B represents a heterocyclic group such as: 3,5-dioxo-(2H,4H)-1,2,4 triazine substituted in position 2 (IIIa); 3-oxo-(2H)-1,2,4 triazine substituted in position 5 (IIIb); 3,5-dioxo-6-amino-(2H,4H)-1,2,4-triazine (IIIc) in which R represents a C1-C3 alkyl group. The invention also concerns the salts of compounds of general formula I with pharmaceutically acceptable acids. It also concerns the various “cis” and “trans” isomers and the various enantiomers with asymmetric carbons.
本发明涉及一种新型环己烷衍生物,其在通式(1)中的1,4位置上二官能团化,其中A代表类似(IIa)的基团,其中Ar本身代表芳香结构,例如苯基或嘧啶基,可选地被一个或多个基团如C1-C3烷基,C1-C3烷氧基,三氟甲基或卤素(IIb)取代;B代表杂环基团,例如:在位置2取代的3,5-二氧代-(2H,4H)-1,2,4-三嗪(IIIa);在位置5取代的3-氧代-(2H)-1,2,4-三嗪(IIIb);3,5-二氧代-6-氨基-(2H,4H)-1,2,4-三嗪(IIIc),其中R代表C1-C3烷基。本发明还涉及通式I化合物与药学上可接受的酸形成的盐。还涉及具有不对称碳的各种“顺式”和“反式”异构体以及各种对映体。